The aim of present study was to characterize the pharmacological profiles of K579. During repetitive glucose loading using Zucker fatty rats, pretreatment with K579 attenuated the glucose excursion after the first and second glucose loading. The kinetic study revealed that K579 was a more potent and slower binding inhibitor than the existing dipeptidyl peptidase IV inhibitor, NVP-DPP728.